share_log

Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial

Benzinga Real-time News ·  Jun 29, 2022 19:50
  • Can-Fite BioPharma Ltd (NYSE:CANF) announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis.
  • The study data show that patients treated with oral Piclidenoson 2 mg or 3 mg twice daily had clinically equivalent efficacy responses. 
  • At week 16, patients receiving Piclidenoson 3mg demonstrated statistically significant improvement compared with placebo, as measured by the Psoriasis Area and Severity Index (PASI) 75 response - Piclidenoson 3mg: 9.7% vs. placebo: 2.6%. 
  • Related: Can-Fite BioPharma Flags Delay In Piclidenoson Data Readout From Psoriasis Study.
  • Secondary endpoint parameters at week 32 comparing Piclidenoson to the active control drug, Amgen Inc's (NASDAQ:AMGN) Otezla (apremilast), revealed inferiority related to PASI 75 (17% vs. 26.2%) and PASI 50 (34.1% vs. 49.5%).
  • But revealed the superiority of Piclidenoson compared to Otezla in the Psoriasis Disability Index (PDI) (20.5% vs. 10.3%).
  • Piclidenoson showed a favorable safety profile.
  • Price Action: CANF shares are up 33.8% at $1.19 during the premarket session on the last check Wednesday.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment